Oligometastasis in Prostate Cancer: Can We Learn from Those "Excluded" from a Phase 2 Trial?

Glicksman, Rachel M; Murad, Vanessa; Santiago, Anna T; Liu, Zhihui; Ramotar, Matthew; Metser, Ur; Berlin, Alejandro

Glicksman, Rachel M; Murad, Vanessa; Santiago, Anna T; Liu, Zhihui; Ramotar, Matthew; Metser, Ur; Berlin, Alejandro.

Afiliación

Glicksman RM; Department of Radiation Oncology, University of Toronto, Toronto, Canada.
Murad V; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Santiago AT; Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Canada.
Liu Z; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Ramotar M; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Metser U; Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Berlin A; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

Eur Urol Open Sci ; 52: 79-84, 2023 Jun.

Article en En | MEDLINE | ID: mdl-37284049

Palabras clave

Metastasis-directed therapy; Oligometastasis; Positron emission tomography; Prostate cancer; Prostate-specific membrane antigen

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Eur Urol Open Sci Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google